Cara Therapeutics (GB:0HTC)

Cara Therapeutics (0HTC) Share Price & Analysis


0HTC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.04 - $12.86
Previous Close$3.32
Average Volume (3M)1.73K
Market Cap
Enterprise Value$200.21M
Total Cash (Recent Filing)$47.80M
Total Debt (Recent Filing)$77.42M
Price to Earnings (P/E)N/A
Aug 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding53,983,227
10 Day Avg. Volume211
30 Day Avg. Volume1,726
Standard Deviation0.16
Financial Highlights & Ratios
Price to Book (P/B)1.27
Price to Sales (P/S)165.95
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.63
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda-2.36
Price Target Upside386.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7




What was Cara Therapeutics’s price range in the past 12 months?
Cara Therapeutics lowest share price was $3.04 and its highest was $12.86 in the past 12 months.
    What is Cara Therapeutics’s market cap?
    Currently, no data Available
    When is Cara Therapeutics’s upcoming earnings report date?
    Cara Therapeutics’s upcoming earnings report date is Aug 07, 2023 which is in 60 days.
      How were Cara Therapeutics’s earnings last quarter?
      Cara Therapeutics released its earnings results on May 15, 2023. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.023.
        Is Cara Therapeutics overvalued?
        According to Wall Street analysts Cara Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cara Therapeutics pay dividends?
          Cara Therapeutics does not currently pay dividends.
          What is Cara Therapeutics’s EPS estimate?
          Cara Therapeutics’s EPS estimate is -$0.54.
            How many shares outstanding does Cara Therapeutics have?
            Currently, no data Available
            What happened to Cara Therapeutics’s price movement after its last earnings report?
            Cara Therapeutics reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went up 13.091%.
              Which hedge fund is a major shareholder of Cara Therapeutics?
              Among the largest hedge funds holding Cara Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Cara Therapeutics’s shares valued at 10M.


                Cara Therapeutics Stock Smart Score

                The Cara Therapeutics Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Cara Therapeutics

                CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics. Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Cara Therapeutics
                Crispr Therapeutics AG
                Fate Therapeutics
                Gilead Sciences

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis